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The Functional and Structural Consequences of Aberrant
Microglial Activity in Major Depressive Disorder

Abstract
Major depressive disorder (MDD) is a highly debilitating neuropsychiatric illness
which has been linked with increases in both peripheral and central inflammation, as well
as with changes in connectivity. Although countless studies have investigated these two
topics, the relationship between neuroinflammation and functional/structural connectivity
has not been explored. Using [18F]FEPPA PET imaging, we measured translocator
protein-related (TSPO) microglial activity in the subgenual anterior cingulate cortex
(sgACC) and insula and confirmed significantly increased [18F]FEPPA uptake in
depressed patients (N=12) compared to healthy controls (N=23). Using a seed-based ROI
analysis of fMRI data, we found that patients show overall decreased connectivity
between the sgACC and the insula. To test the relationship between inflammation and
brain connectivity, we performed regressions which found functional (sgACC-insula) and
structural (cingulum bundle) connectivity to be significant factors in explaining the
microglial activity in the left sgACC. Our study suggests that neuroinflammation relates
to network function in MDD.
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Summary for Lay Audience
Major depressive disorder is a brain illness which affects many people worldwide.
The main symptoms are depressed mood and loss of pleasure, with additional symptoms
such as lack of concentration and fatigue. Previous studies have shown that there are a
variety of reasons why depression could occur, but the focus of the current thesis is the
inflammation hypothesis. In the brain, when the inflammatory response is activated,
microglia, the resident immune cells in the brain, will become activated. Microglia
influence the body’s inflammatory response, and their activation can be measured through
positron emission tomography (PET) imaging of a protein on their surface. It has been
shown in the past that certain areas of the brain have greater microglial activity in
depression.
The functioning of different brain areas also plays a role in the development of
depression. The simultaneous activation of areas such as the anterior cingulate cortex and
the insula can be disrupted due to depression; this simultaneous activation represents an
activation-related connectivity between the regions. Those two areas are involved in
mood and self-examination. We can measure levels of activation of specific brain areas
with magnetic resonance imaging (MRI). What we do not know is how disrupted brain
connectivity is related to microglial activity in these areas.
The first goal of this thesis was to measure brain inflammation through microglial
activity, particularly in areas noted by other studies. The second goal was to measure
brain connectivity between these areas in the brain. The third goal was to see if brain
connectivity and microglial activity are related in any way. We expected increased
inflammation and decreased brain activity in depressed individuals. We also expected that
they would be related to one another.
We found that, as we predicted, in these brain areas inflammation was increased
and brain activity was decreased in depression. We next found that brain connectivity is
related to inflammation. We believe that the continuous study of the neurological basis
for depression will help physicians and pharmaceutical scientists develop new and more
specific treatments to better the lives of the many of those who suffer from depression
worldwide.
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Chapter 1
1 Depression, Its Burden, and the Knowledge Gap
This thesis contains research pertaining to the etiology of major depressive
disorder (MDD), a highly debilitating mental illness. Mental illnesses negatively impact
an individual’s mood, thoughts, or behaviour, leading to distress and impairment in daily
activities. Depression is the most common of all mental illnesses and the leading cause of
disability worldwide, having a lifetime prevalence of 20.6% in the US and 11.2% in
Canada, and while manageable when treated, can have serious implications for quality of
life when left unmanaged (1,2). There exists no one-size-fits-all cure for MDD; it is
hypothesized that many different physiological pathways can contribute to its
etiopathology. Modern treatment options rely on symptom management and include a
combination of medication (selective serotonin reuptake inhibitors etc.) and
psychotherapies. Despite the various options that are available, many patients develop a
treatment-resistant state. In part, resistance may relate to our failure to address the
mechanistic processes that underlie the illness. This thesis is an attempt to investigate one
such pathway – neuroinflammation – in MDD. Several lines of clinical research on
neurobiological pathways of depression, reviewed below, point toward depression being a
systemic disorder with an inflammatory basis. The aim of this work is to fill the
knowledge gap linking the notion of neuroinflammation to depressive symptoms and
behaviours mediated by dysfunctional brain networks.

1.1 Clinical Symptoms of Depression
1.1.1 Major Depressive Disorder (MDD)
MDD is a psychiatric illness which tends to run a remitting and relapsing course.
It is common to experience multiple episodes; about 75% of individuals who have
experienced a single episode of MDD will experience two or more at different points
throughout life. With each subsequent episode, the risk of having another one increases
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exponentially, while the time between each episode decreases (3,4). For an individual
who has had at least one episode, the average number of MDD episodes is four, and each
episode has an average length of twenty weeks (5,6). To be diagnosed with MDD, as
defined by the Diagnostic and Statistical Manual of Mental Disorders 5 (DSM-5), one
must have at least five of the following symptoms, with one of them being either
depressed mood or loss of pleasure: depressed most of the day; diminished pleasure in
activities all day or most of the day, every day; weight loss or weight gain without dieting
or increase/decrease in appetite nearly every day; insomnia or hypersomnia almost every
day; psychomotor agitation or retardation; fatigue; feelings of worthlessness or guilt;
diminished ability to think; and recurrent thoughts of death or suicide ideation. The
symptoms must cause distress or impairment in living and completing regular tasks, and
the individual must not have experienced a manic episode. Each case of depression
presents a varied combination of symptoms, and varied trajectories of outcomes, which
has led to the notion that multiple distinct etiologies exist for this condition. For example,
some with depressed mood may have pathophysiology associated with the medial
prefrontal cortex, while others with predominant anhedonia and alterations in motivation
may show a decrease in dopaminergic activity in the mesocortico-limbic pathway (7,8).
These pathophysiological changes may also coexist in the same individual and may
fluctuate over the illness course.
1.1.2 Impact of MDD
Depression affects over 168 million people around the globe, two thirds of whom
are women, being one of the major contributors to reduced quality of life (9,10). In
Canada, about 8% of adults will have had at least one MDD episode throughout their
lives (11). Individuals with MDD are more likely to be hospitalized and are at increased
risk of suicide. As well, they are two times more at risk of unemployment than those
without MDD (12–14).
Depression causes noteworthy economic and social burden; in Canada, mental
health spending is projected to rise into the trillion dollar range by 2031 (15). Depression
causes patients to become less productive; those with depression will lose 5.6 hours of
productive time at work per week compared to non-depressed workers who will lose 1.6
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hours (16). This equates to 225 million lost workdays and $36.6 billion lost in salary per
year in the US, and an additional cost of about $32.3 billion per year to the Canadian
economy (4,17).
The negative effects are not limited to the social, as depression increases rates of
morbidity and mortality. The physical impairments seen in depression are of a similar
magnitude to those in chronic diseases such as diabetes and cancer (18). Depression is
correlated with a subsequent cardiovascular episode, its associated mortality, as well as
with increases in risk for cardiovascular disease, stroke, and hypertension; the risk of any
cardiovascular event increases by 20% in individuals with four or more depressive
symptoms as compared to those without (19–25). Individuals with depression are eleven
times more likely to attempt suicide than healthy individuals, and about one in ten will
attempt suicide (14,26,27).
1.1.3 Late-Life Depression (LLD)
While depression in the adult population has been somewhat better delineated,
late-life depression (LLD) – depression occurring in an older population – is likely
different in terms of etiopathogenesis and presentation. The specific criterion of age for
LLD has not been widely agreed upon at this time, but the age of qualification for
geriatric psychiatry-related services, i.e. greater than 65 years, has been considered to be
most acceptable. The participants in the study were older (over the age of 50, with some
over the age of 65), therefore the symptomatology specific to LLD should be considered.
As is the case with MDD, individuals must have an episode lasting at least 2 weeks with
one of the primary symptoms (anhedonia and depressed mood) and at least four of the
secondary symptoms as previously described. The DSM-5 criteria seem to fail in
diagnosis of late-life adults as complaints about failing bodily functions will be written
off as expected for the age bracket (28). Help-seeking behaviour which comes in the form
of persistent grievances with fatigue, pains, and headaches can be easily overlooked. As a
result, depression in the elderly is underdiagnosed and undertreated. While there is
growing interest in better defining LLD, there have simultaneously been attempts to
develop screening tools to characterise LLD-specific symptoms of depression. Of these
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the self-rated Geriatric Depression Scale (GDS) has been validated in capturing some of
the typical somatic symptoms experienced by patients suffering from LLD.
1.1.4 Impact of LLD
More than 300,000 of the elderly in Canada are depressed, and this is associated
with $5 billion in health care costs per year -- a number which ever-growing in today’s
aging population (29). 1 in 10 of older adults are diagnosed with LLD at some point in
their life (30). Older adults in the community with depression have a prevalence of
11.2%, but institutionalized older adults have even higher rates (30). 12-45% of LLD
patients in hospitals reported symptoms of depression, and 12.4% of those in care homes
had major depression (31,32). Those in care homes tend to be placed there as a
consequence of caregivers becoming overwhelmed with the increasing demand and
mental load needed for elderly care.
LLD is associated with both non-suicide and suicide mortality in older adults
(33,34). In a Statistics Canada study, it was found that 19% of the suicide victims in
Canada were over the age of 60, and of those men made up the majority. LLD patients
may be more likely to commit suicide through more violent and deadly means, with 26%
of suicide victims over 60 using firearms compared to only 12% of those aged 15-39 (35).
1.1.5 Late-Life Depression vs. Adult Depression
LLD is symptomatically distinct from adult depression, with LLD patients, for
example, having a pronounced fear of falling (36,37). The stressors specific to late-life -forced retirement, chronic illness, cognitive decline, social isolation, caregiving, financial
distress, loss of independence, and bereavement -- can create an environment which leads
to the development of LLD (38). Views towards life and death itself will be unique to
older individuals as compared to those who are younger (39). Those with greater harm
avoidance, insecure attachment, low extraversion, neuroticism, low self-esteem, no sense
of greater purpose, no social roles, and lower education will be at greater risk for
developing LLD. As well, those of the female sex and with nutritional deficits, especially
in vitamin B12 and folates, will likewise be predisposed to depression (40).
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Unlike depression associated with adult age, LLD is oftentimes comorbid with allcause dementia (1.85, 95% CI 1.67-2.04, P<0.001), Alzheimer’s disease (1.65, 95% CI
1.42-1.92, P<0.001), and vascular dementia (2.52, 95% CI 1.77-3.59, P<0.001) (41).
Depression can be a signalling factor for dementia, and some claim that LLD is a risk
factor for mild cognitive impairment and neurodegenerative diseases (causation has not
been determined in this case). Comorbidities with other medical illnesses in LLD can
affect scores on rating scales; elevated scores for eight items from the Hamilton Rating
Scale for Depression (HAMD, Hamilton, 1960) have been observed in individuals over
the age of 70, likely due to such somatic comorbidities (42). In addition, it seems that the
pathways underlying depression in older populations may differ. For example, white
matter hyperintensities have been revealed to play some role in the development of
depression while their presence in younger adults is uncommon (43). Despite knowledge
of dissimilar physical symptoms in adult and late-life depression, differences between the
treatment of these two groups have not been distinguished and refined, an oversight
which has left many older adults with insufficient resources to manage their symptoms.

1.2 Treatment of Depression
1.2.1 Treatment Options
The treatment of depression can be divided into three broad categories:
medication, psychotherapy, and alternative treatments. For the purposes of this thesis, we
will be focusing on the former. Each type of treatment can be offered alone, but it is
recommended to receive them in combination to gain maximum benefit. Medications, or
antidepressants, are the most relied-upon treatment and come with a variety of options.
Selective serotonin reuptake inhibitors (SSRIs) are the most prescribed of the
antidepressants. They act by blocking the reuptake of serotonin and therefore increase
serotonin signalling. Other types of antidepressants such as serotonin and norepinephrine
reuptake inhibitors (SNRIs), 5-HT1A receptor antagonists, and dopamine reuptake
blockers function similarly with the basic principle of regulating levels of
neurotransmitters (namely serotonin, norepinephrine, and dopamine) in the brain. Most
common forms of antidepressants target monoaminergic mechanisms which were
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discovered many decades ago; no novel drug therapies have entered the market except for
esketamine, a ketamine-derived glutamate receptor blocker which was FDA-approved in
2019, and agomelatine, a melatonin receptor agonist approved for use in Europe in 2009
and Australia in 2010. Interestingly, within the last decade the monoaminergic hypothesis
of SSRIs has been questioned, and has even been speculated that their mechanism of
actions may hinge upon anti-inflammatory pathways (44).
Anti-inflammatory approaches have been considered for the treatment of
depression as either add-ons or monotherapy (to be further discussed in Section 1.5.6)
(45). Nonsteroidal anti-inflammatory drugs (NSAIDs), the most studied of the antiinflammatory drugs, have been found to have anti-depressant effects when compared to
placebos and are inexpensive and easy to obtain (46). Their effectiveness relies upon the
ability to reduce prostaglandins. One class of NSAIDs, selective cyclooxygenase-2
(COX-2) inhibitors, are considered to have a more direct anti-inflammatory effect than
other classes and therefore are more effective as treatments for depression (47–49).
NSAIDs, however, may increase the risk of cardiovascular events (45,50). Cytokineinhibitors, which target cytokine synthesis, concentration, or related receptors, have a
direct anti-depressant effect, although they may increase the risk of infection (46,51).
Other groups of anti-inflammatory drugs which have shown anti-depressant effects
include but are not limited to statins, corticosteroids, and poly-unsaturated fatty acids
(PUFAs) (45).
Despite the potential promise, it is not clear who should receive this treatment and
the overall response rate is minimal as we are not able to stratify patients with
neuroinflammation from those who do not have such inflammatory processes;
furthermore, it is not clear how inflammation, which is generally a short-lived,
constrained defence process, can lead to pervasive depression in those affected. This
mechanistic understanding will help us identify the profile of inflammatory depression as
well as aid in developing more empirically informed therapies. Moreover, the above
treatments, inclusive of antidepressants, may not eliminate the risk of relapse, worsening
of symptoms, or treatment-resistance.

1.2.2 Treatment-Resistant Depression

7
The ultimate aim regarding the above therapies is for the patient to achieve full
recovery– the almost complete absence of burdensome symptoms. However, while they
can be effective for many individuals, antidepressants can have little to no effect in some.
Of those who receive “adequate” treatment for MDD, about 70% will respond to
treatment, yet only 50% will fully recover; the remaining patients will not respond at all
(52,53). Other studies suggest that this value is even lower, with only 30% reaching the
goal of full remission, and those previously classified as responsive experiencing residual
symptoms such as fatigue and insomnia, contributing to increased risk of relapse (54–56).
Those who do not sufficiently respond are referred to as having treatment-resistant
depression (TRD). No consistent definition of this phenomenon exists, and clinicians may
diagnose a patient if they do not respond to antidepressants whatsoever, or if they do not
reach full remission after adequate dosing and course duration. Despite these differences,
a concurrence between each definition is that to be diagnosed with TRD, one must fail to
adequately respond to at least 2 courses of different antidepressants within an appropriate
period of time.
Of those who respond minimally, treatment resistance may arise from being
prescribed a suboptimal dose, an unsuitable medication course, or discontinuing
medication altogether. This is further complicated by comorbidities with illnesses such as
anxiety and the heterogenous nature of depression itself, which make it difficult to
develop universally effective treatments. Misdiagnosis due to these factors is not
uncommon, and the inconsistency in TRD’s definition contributes to improper
prescriptions of pharmacotherapies.
The disregard for the disparity in symptomatology and disease progression
between adult and late-life depression makes this issue even more pressing for the elderly.
Atypical symptoms, somatization, cognitive decline, lack of education about drug
therapies, and a lack of support from family can all contribute to cases of treatmentresistant late-life depression (TRLLD) (57). The spectrum of possible depressive
symptoms in older adults can range to bodily complaints such as stomach-aches and
palpitations, present in about 20-80% of older patients but not commonly described in
younger patients, leading to the belief that these individuals are experiencing side effects
and therefore prematurely stopping treatment (28). While the response rates for older
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adults are similar to those below the age of 50, it has been shown that the same cannot
always be said about the time course. In the first 6-12 weeks of treatment, over 80% of
those with TRLLD will fail to respond sufficiently or will experience early relapse
(58,59).
TRD is immeasurably onerous for those it affects. An inability to find relief from
its physical and mental demands is taxing. It is easy to forget about the financial burden:
those with TRD will be subject to increased medical costs compared to those who
respond to treatment (60). They are more likely to be hospitalized and their hospital visits
are six times the cost of a treatment-sensitive individual (61). It becomes apparent that
establishing concrete means of diagnosing TRD and TRLLD is incredibly important.

1.3 Explaining Depression – Inflammation as a Factor in its Development
Social as well as biological factors such as genetics, aging, and physical diseases
appear to have an effect on one’s mental health. The interplay between all of these factors
and the degree of their severity may ultimately be what leads to depression, but the
impact of each alone cannot be discounted (62). Predisposing factors may act on brain
systems such as the frontolimbic networks and may bring about the vulnerability for
depression, and promote chronicity and relapse (63). Etiological factors such as vascular
changes, amyloid deposits, inflammation, and genetics may cause direct damage to
reward, salience, and cognitive control networks, or may further increase the severity of
the predisposing factors. Social stressors may lead to inflammation, oxidative stress,
altered functional connectivity, or neurogenesis (64). These stressors may impact the
brain in the same way as aging or disease-related processes. Social withdrawal behaviours
associated with depression are linked with a desensitization of the hypothalamuspituitary-adrenal (HPA) axis due to dampening of a prolonged stress response (38). Stress
may also lead to a direct neglect of health. All in all, the various ways through which
depression may occur are diverse and numerous. The cause of depression cannot be
explained by a single factor and requires a complete understanding of several interacting
etiological factors. However, the mechanisms of each factor are still unclear and should
be studied in depth in order to gain a better understanding of how each etiological factor
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works independently or synergistically and additively with other factors to produce
depression.
A widely considered mechanism for depression is neuroinflammation which is
part of the body’s immune response -- a line of defense against infection and injury. The
immune response can be classified into two categories: innate or acquired. The innate
system is driven by white blood cells, while the acquired system consists of an
immunological memory involving antigens and T and B lymphocytes. The question of
whether the immune response involved in depression, a component of which being
inflammation, is acquired has long been debated, but research has shown that there are
increased T cell factors, implicated in both innate and acquired responses, in depressed
individuals, suggesting that both systems may be at play (65,66). Despite having some
answers to this broad and undeniably elemental question, it is only a small facet of the
system at large and is representative of the larger dilemma seen in this field: there is a
current lack of understanding of the complexity of the relationship between inflammation
and MDD.
Complicating the matter further, inflammation can occur throughout the body and
is present in a number of conditions, such as allergies, autoimmune diseases, and
infections. This is inclusive of depression, which seems to be the main neuropsychiatric
illness explained by brain tissue inflammation, but brain inflammation may play a role in
the aetiologies of several other brain illnesses including schizophrenia, Parkinson’s,
epilepsy, and Alzheimer’s. The focus of this thesis is on neuroinflammation as a theory
explaining the development of MDD. The following is an overview on
neuroinflammation-related findings for MDD, including relevant tools for its
measurement and mechanisms of action.

1.4 The Anterior Cingulate Cortex and Insula as Important Nodes of
Functional Connectivity in Depression
A variety of brain networks involved in processing of emotional information are
thought to be relevant to the pathophysiology of depression. Two areas of the brain which
have been repeatedly linked with response to and diagnosis of depression and have
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displayed evidence of involvement in neuroinflammation (to be further discussed in
Section 1.5.8) are the insula and the anterior cingulate cortex (ACC). The insula, an area
with connectivity to depression-related regions, including the subgenual ACC (sgACC),
which is involved in processing salient stimuli and regulating interoception (67,68),
exhibits dysregulated functional connectivity (or temporal correlation with separate
brain regions) in individuals with MDD (69–73). Such dysregulation has been associated
with the development of a variety of cardinal features of MDD, including loss of pleasure
(74–76). More precisely related to treatment of depression, its activity is altered as a
result of depression treatment and can predict treatment outcomes. Antidepressants
reduced insular activity (77,78) while regional cerebral blood flow in the insula was
reduced with repetitive transcranial magnetic stimulation (rTMS), a popular treatment for
TRD (79). Additionally, the right anterior insula was identified as a key factor in
responsiveness to CBT or antidepressants (80). In a particularly insightful study using the
insula as a seed region, the effective connectivity, or the influence one neural system
exerts over another (81), of the insula with the dorsomedial prefrontal cortex (DMPFC)
and from the pulvinar and visual cortex to the insula were shown to be diminished, which
suggests a debilitated connection between the insula and higher processing as well as
sensory regions in MDD (82).
Marrying the concept of treatment response and effective connectivity using
rTMS, Iwabuchi et al. (2019) demonstrated that pre-treatment fronto-insular effective
connectivity predicted response to rTMS treatment at 1 month in those with TRD, while
right anterior insula cerebral blood flow was negatively correlated with the same
treatment outcome, further cementing the insula’s role in depression-involved brain
networks (83). The above studies highlight the differential relationship the insula has with
regions such as the DMPFC in MDD, a relationship which is modulated by treatment
response, and how insula physiology can be improved with depression-targeted
treatments.
Similarly, the ACC and sgACC are dysregulated in MDD, but interestingly,
dysregulation of the sgACC’s connectivity with the insula has been consistently reported
in MDD (71,84–88). The sgACC’s connectivity can be improved with and can predict the
response to rTMS application to the dorsolateral prefrontal cortex (DLPFC) (89,90). This
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is not limited to rTMS; the baseline functional connectivity between the sgACC and
superior frontal/temporal gyrus, as well as between the sgACC and the middle temporal
gyrus predicted electroconvulsive therapy (ECT) response (91). In 2018, Weigand et al.
found that depressive symptom improvement was predicted by the functional connectivity
between the sgACC and the DLPFC, solidifying the sgACC’s importance in depression
symptomatology and outcomes (92). Of relevance to the topic of the current study,
increased sgACC activity can predict treatment resistance (93), and symptom
improvement with, for example, ketamine, can normalize its hyperactivity (94). Such
findings have made the insula and the ACC attractive targets for depression studies but
there is still much left unexplained, especially regarding their role in neuroinflammation.
In the current study, we focus on inflammation present in the sgACC and insula, and how
this relates to their connectivity in MDD.

Figure 1.1. Axial view of the insula and sgACC. The right and left insula (yellow) are
functionally connected to the left and right sgACC (red). We expect a weaker
connectivity between the sgACC and insula in depressed individuals (associated with
increased neuroinflammation) compared to healthy individuals.
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1.5 Findings Concerning Inflammation and Depression
1.5.1 Mechanisms of the Neuroinflammatory Response
There exist many inter-related theories as to how inflammation increases
depressive symptoms, but for the purposes of this overview we will focus on three: HPA
axis-modulated neuroendocrine dysfunction, infection, and microglial activation. The first
of these theories involves the stress hormone system, the HPA axis. In response to
stressors, the HPA axis signals for the release of glucocorticoids by the adrenal glands,
which act on organs throughout the body to regulate physiological processes and have a
negative feedback effect at various levels of the system (95). In depressed individuals,
this system can become dysregulated, demonstrating higher sensitivity to hormones,
particularly adrenocorticotropic hormone (ACTH), and higher levels of glucocorticoids,
which may be a result of disrupted negative feedback (96–100). Glucocorticoids are well
known to have anti-inflammatory effects, notably through glucocorticoid receptormediated suppression of pro-inflammatory transcription factors, leading to decreased
levels of pro-inflammatory cytokines and chemokines (101–104). These
immunosuppressive effects can also occur through interaction with proinflammatory
signalling pathways and can induce destruction of immune cells such as T lymphocytes
(105). Although the anti-inflammatory effects of glucocorticoids have been studied in
depth, they can likewise have pro-inflammatory properties through, for example,
interactions with pro-inflammatory cytokines, an effect which seems to be exacerbated by
stress (106–109).
MDD is more highly prevalent in individuals with inflammation-related disorders
– including but not limited to arthritis, cardiovascular diseases, multiple sclerosis, and
diabetes – and it is possible that chronic systemic inflammation as a result of illness may
contribute to MDD pathophysiology (110). When an individual becomes sick, they will
experience a set of symptoms very similar to those of depression: fatigue, loss of
motivation, anhedonia, and loss of pleasure, among others. This is categorized as
“sickness behaviour,” and while different from depression itself due to its short-lived
presence (only as long as the illness lasts), such symptomatology suggests that individuals
who do develop MDD may be more susceptible or have been subjected to an intense or
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long-lasting inflammatory response which has continued beyond the illness duration
(111,112). During an illness, proinflammatory cytokines are produced at the site of
infection and can proliferate throughout the body, traveling to the brain to cause
depression-like symptoms and depression disorders through means such as the neural
pathway which can activate primary afferent nerves like the vagus nerve or the humoral
pathway which involves the choroid plexus (113–117).
An additional pathway exists in the brain through which systemic inflammation
can exert its effects, and that is by activating microglia in the brain, thereby triggering a
neuroinflammatory state. Due to the significant mounting evidence and new means of
measuring microglia in vivo in humans, we are currently interested in this final theory.
Microglia are involved in the neuroinflammatory response by acting as macrophages and
can be measured as a proxy for inflammation. While there are multiple methods through
which their activation can occur, a specific example of a mechanism describing the
activation of microglia and how this results in negative outcomes involves the activation
of indoleamine 2,3 dioxygenase (IDO), which breaks down tryptophan (TRP), a serotonin
precursor, into kynurenine (KYN) (Figure 1) (111,118–120). Serotonin is well-known as
an essential monoamine neurotransmitter involved in mood and cognition, and formation
of KYN bypasses the pathway through which it is formed. This process results in
decreased serotonin, which is similar to what individuals injected with interferon alpha
(IFN-α), an inflammatory biomarker, who develop depression experience: decreased
serotonin and increased KYN (121). KYN can also lead to the production of kynurenic
acid in astrocytes and quinolinic acid in microglia (119). This has been implicated in
causing oxidative stress, a process involving an increase in reactive oxygen species,
leading to tissue damage (119,122). It has been reported that depressed suicide victims
exhibit increased levels of quinolinic acid in the microglia of the ACC post-mortem
(123). Those with chronic illnesses who are being treated with interferon alpha (IFN-α)
manifest decreased TRP, increased KYN and KYN/TRP ratio, and increased depression
scores (124). Healthy individuals, when faced with an inflammatory challenge,
experience an activated KYN pathway, as well as increased IDO (125,126). Injection of
quinolinic acid precursor 3-hydroxykyneurinine (3-HK) into mice leads to depression-like
behaviours, and inhibition of IDO through an IDO inhibitor reduces these behaviours

14
(126–129). While the KYN pathway is not the only one which is associated with
microglia, it seems to be strongly involved in the neuroinflammatory condition of
depressed individuals.

Astrocyte

Microglia

Figure 1.2. Kynurenine pathway of microglial activation – one of many contributors
to neuroinflammation. Stress leads to increased inflammation in the body and brain,
thereby increasing pro-inflammatory cytokines and leading to the activation of
indoleamine 2,3 dioxygenase (IDO) and kynurenine-3-monooxygenase (KMO). IDO
breaks down tryptophan (TRP) into kynurenine (KYN) while KMO facilitates the
production of 3-hydroxykyneurinine (3-HK), eventually leading to quinolinic acid
(QUIN) in microglia and oxidative stress. Kynurenine aminotransferase (KAT) catalyses
the conversion of KYN to kynurenic acid (KYNA) in astrocytes.
1.5.2 Peripheral Inflammatory Markers
Measurements of peripheral inflammatory biomarkers are a simple method of
assessing and confirming inflammation in the body. Inflammatory biomarkers, including
but not limited to cytokines and acute phase proteins, are released by the body during
immune processes and are exhibited in dysregulated amounts in those with
neuropsychiatric illnesses. Previous studies over the last century have shown peripheral
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increases in proinflammatory cytokines like INF-α and interleukin-6 (IL-6) in depression
(130). Other inflammatory markers which are elevated in depression include acute phase
proteins, chemokines, adhesion molecules, and inflammatory mediators like
prostaglandins. These elevated levels even occur in those without any other recorded
illnesses and in post-mortem brain tissue samples (131). Peripheral blood markers
interleukin-1β (IL-1β), IL-6, tumour necrosis factor (TNF), and C-reactive protein (CRP)
are the most reliable biomarkers of inflammation in individuals with MDD, as noted by
numerous meta-analyses (130). Further, biomarkers such as TNF have been associated
with genes involved in depression when involved in the immune response (132). Chronic
elevation of these cytokines may lead to the adverse symptomatology of depression, and
an increase in symptom severity is correlated with an increase in peripheral blood
cytokine concentrations (133,134), although not every person with depression will have
elevated levels of proinflammatory cytokines (130,135,136). This can be attributed to the
heterogenous nature of depression. All in all, increases in proinflammatory cytokines
observed in depression are the most basic means through which inflammation has been
linked to depression.
Levels of certain inflammatory biomarkers can be modulated using
antidepressants. In a meta-analysis containing 22 different studies pertaining to
antidepressant effect in MDD, it was found that IL-1β and IL-6 and depressive symptoms
were decreased in those who had undertaken antidepressant therapy, expressly SSRIs
(137). Wang et al. (2019) demonstrated that this is also the case with TNF (138). These
studies effectively proffer a relationship between inflammatory markers and the
expression of depression – a relationship which can be managed in part with therapies
specifically targeting depression.
In addition to increased innate levels of proinflammatory cytokines,
administration of these cytokines can induce depressive symptoms. Administration of
innate human cytokines such as TNF-α can lead to psychosis, delirium, and agitation,
while administration, both acutely and chronically, of cytokine inducer
lipopolysaccharide (LPS) in healthy volunteers leads to an increase in symptoms of
depression (111,133,134,139). Individuals with established medical conditions see similar
results; peripheral cytokine levels are increased in those exhibiting depressive symptoms
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as a result of medical conditions, but who themselves were not originally clinically
depressed (140,141). 35.6% of individuals with asthma experienced symptoms of
depression, and those who were depressed had higher levels of TNF-α (142), while
illness-induced increases in IL-6 and nuclear factor kappa B, which is involved in the
initiation of the inflammatory response, are correlated with depressive symptoms such as
fatigue and insomnia (143,144). These “sickness behaviours,” as mentioned before, will
disappear once the illness has ceased, but dysregulation of the inflammatory system may
prolong their presence and this chronic exposure may contribute to MDD. In actuality,
those with a medical illness are several times more likely to develop MDD (145).
In related experiments, blocking cytokines such as TNF or other units of the
inflammatory pathway, such as COX-2, has resulted in a reduction of depressive
symptoms in individuals with medical conditions such as arthritis and cancer, and in
individuals with MDD (46,146). From these findings it is apparent that inflammation at
the systemic level is deeply intertwined with depression symptomatology which lends
credibility to the infection theory of inflammation. Again, this is not the case in every
individual with increased inflammatory markers or an inflammatory medical condition,
which suggests that a specific faction of individuals is vulnerable to inflammation-derived
depression.
All this considered, the presence of inflammation alone is not enough to describe
depression symptomatology. Inflammation is present in several neuropsychiatric illnesses
including schizophrenia and obsessive-compulsive disorder, suggesting that it is possible
inflammation has a multitude of neurological outcomes or a specific combination of
biological factors must be present in order for the effects of inflammation to contribute to
depression precisely.
1.5.3 Blood Brain Barrier Permeability
Until recently, it was not well understood how peripheral cytokines affected or
were involved in the etiopathogenesis of depression at the level of the brain. As they exist
in the plasma and are seemingly blocked from entry into brain parenchyma by the blood
brain barrier (BBB), their connection to the brain was thought to be indirect (e.g., neural
and humoral pathways which target the afferent nerve). Permeability in the BBB was
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shown to be caused by chronic social stress in male mice. In the nucleus accumbens
(Nac), an area associated with emotional regulation, claudin-5 (cldn5), a tight junction
protein which acts as a cell adhesion molecule in the paracellular barrier between
endothelial cells, is reduced and peripheral proinflammatory cytokines flow into the
brain, leading to depression-like behaviours such as social avoidance, anhedonia, and
helplessness. This process has been observed in post-mortem brain tissue samples of
humans with MDD, effectively associating changes in the Nac endothelium with
depression in humans (147,148). Other means through which peripheral cytokines may
enter through the BBB include entrance of cytokines through leaky regions such as the
circumventricular organ, passage of immune cells that generate cytokines into the brain,
active transport, and increased inflammatory mediator signalling leading to production of
inflammatory cytokines by microglia and subsequent BBB disruption (149–151).
1.5.4. Cytokines and Brain Activity
Since cytokines can enter the brain, it would be of interest to measure them in the
brain along with their direct effects on brain activity. Unfortunately, levels of cytokines in
the brain have been studied in most part using post-mortem samples (which are not fully
generalizable), but the relationship between cytokines, brain activity, and brain
connectivity has been a topic of interest with the development of more sophisticated
neuroimaging technologies. The results of these studies demonstrate that there is an
association between inflammation and dysregulation of both activity and connectivity of
specific brain regions. Individuals treated with IFN-α have increased activation in the
dorsal anterior cingulate cortex (dACC), increased arousal anxiety, and an increased
alarm response (152). In an experiment, when subjected to a public speaking task subjects
exhibited increased concentrations of oral IL-6 and soluble TNF receptor 2 (sTNF-R2),
which was correlated with activation of the dACC in a social rejection task. In addition,
activation of the amygdala was correlated with increased oral IL-6 expression in response
to a social evaluation stressor, with participants who had the greatest IL-6 responses
demonstrating the greatest connectivity in the fear network (amygdala, DMPFC).
On the contrary, increased IL-6β has been associated with decreased activity in
the anterior cingulate and amygdala, and increased likelihood of treatment resistance
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(153). Likewise, an increase in CRP was associated with a reduction in functional
connectivity in a network including the ventral striatum, para-hippocampal
gyrus/amygdala, orbitofrontal and insular cortices, and posterior cingulate cortex (154).
These changes in connectivity were focused on the ventral medial prefrontal cortex
(VMPFC), which mediates the relationship between CRP and anhedonia. While these
results are the opposite of those mentioned previously, they all indicate dysfunction of the
brain during inflammation. Increases in brain activation and connectivity in areas such as
the ACC and amygdala being correlated with stress and inflammation create the
foundation for our understanding of inflammation and its influence on the brain. While
these studies do not include specific measures for depression or depressed subjects, and
therefore cannot be directly related to its pathology, they reveal that inflammation has a
very real effect on brain functionality. Of note, stress and inflammation are both
predisposing factors for depression and their role in these studies allows for speculation
on how depression may be involved (136).
Other studies have found dysregulation of the brain associated with both
inflammation and depression. Functional connectivity between the striatum and the
VMPFC was correlated with increased peripheral IL-6, IL-1B, and IL-1 receptor
antagonists in MDD (155). The striatum is further involved as increased cytokines reduce
its activation with reward networks, and an injection of the typhoid vaccine, an
inflammatory stimulator, can decrease connectivity between it and the subgenual ACC, a
brain area associated with depression (Section 1.5). This connection is mediated by IL-6.
Moreover, the changes seen in the brain are not limited to the functional; the physical
properties of the brain have been shown to be altered in those with MDD. A thinner
MPFC was found in MDD patients with a greater number of depressive episodes, and
CRP level was inversely associated with right MPFC thickness (156). Hippocampal
volume is negatively associated with higher levels of IL-6 and CRP in MDD, a
potentially debilitating effect but not surprising as memory deficits are a recurring and
common symptom of depression (157). What is most meaningful about these results is
their direct linkage to depression; they tie together depression, inflammation, and brain
measures in single studies. This confirmation that there is a relationship between all three,
with seemingly negative physical outcomes, bolsters the need for further investigations
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into their relatedness, as questions pertaining to how cytokines or other inflammatory
markers correlate with specific brain changes, for example, remain unanswered.
1.5.5 Late-Life Depression and Inflammation
Studies investigating factors of inflammation in older depressed populations are
unfortunately relatively rare despite available studies indicating inflammation as a factor
in LLD and age itself furthering an inflammatory state (158). Increased expression of cell
adhesion molecules in the DLPFC (associated with ischemia), of free 8-isoprostane, a
marker for oxidative stress which can lead to chronic inflammation, and other
proinflammatory biomarkers have been demonstrated in LLD (159–162). Decreases in
inflammatory cytokine levels in older adults (mean age 60.3) after practicing meditation,
as compared to a music group, highlight the presence of inflammation in and its
relatedness to depression symptomatology in older adults (163). As previously
mentioned, somatic comorbidities are often predisposing factors of LLD, so it is
interesting that symptoms often complained about in old age such as frailty have been
linked to chronic inflammation (164,165). More recently, a 2020 study by Sonsin-Diaz et
al. found that compared to those who maintained low levels of CRP, older individuals
(mean age 75.5) who have elevated levels of CRP throughout the majority of a 21 year
period experienced depression symptoms of greater severity (166). This is further
supported by Torre-Luque A. in 2019 and Kokkekler MJE et al. in 2020 who both found
that inflammatory dysregulation is associated with increased depression severity in older
adults (167,168). Overall, inflammation seems to play a critical role in the furtherance of
depression in these individuals, and age may intrinsically lead to such outcomes, although
it is not clear the extent to which inflammation affects older adults and if these effects are
more severe.
1.5.6 Antidepressant Effects of Anti-inflammatory Agents
Another link between inflammation and depression is the effect that antiinflammatory agents can have on depressed individuals. A meta-analysis studied the
effects of pro-inflammatory cytokine inhibitors on depressive symptoms, as compared to
placebos. They found that these medications significantly decreased depressive symptoms
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(169). In a study using infliximab, motor retardation, motivation, suicide ideation, and
depressed mood were all significantly improved (170). Two separate meta-analyses found
that in thousands of patients, anti-inflammatory drugs (including NSAIDs) improved
depression symptomatology (171,172). It should be pointed out that these meta-analyses
were performed in those with comorbid inflammatory conditions such as psoriasis, which
are posited to have a separate mechanistic profile. Although these findings do suggest
antidepressant effects of anti-inflammatory agents, the current evidence is not sufficient
for progression to clinical use. It is unknown how anti-inflammatory agents affect specific
depressive symptoms such as fatigue (45). Consideration of potential side effects,
methodology for the identification of treatment-responsive patients, and comorbidities, a
possible risk factor, will need to be completed. Most importantly, replicability of these
findings will need to be achieved – a milestone which remains to be seen. Discrepancies
in methodology have contributed to inconsistent research on the effects of antiinflammatory agents such as NSAIDs, and a consensus on research methodology is
crucial for lending credibility to their use as antidepressants (173). Nonetheless, their use
in research and their ability to have some effect on depression symptomatology create
further evidence associating depression with inflammation.
1.5.7 Treatment Resistance and Inflammation
Little evidence exists at this point to link treatment resistance in depression with
inflammation as measures of inflammation are not commonly assessed in TRD despite
inflammation being an indicator of treatment response and it contributing to the potential
existence of an inflammatory “subtype” of depression (174). Recent research has
suggested that inflammatory dysregulation may be the difference between a treatment
responder and a non-responder (175,176). This is substantiated by low monocyte
chemoattractant protein 1 (MCP1), an inflammatory cytokine, being found to be a
predictor of treatment resistance (177), along with increased peripheral IL-6 in majorly
depressed patients who did not respond to amitriptyline treatment (178). Other peripheral
cytokines, such as TNF, sTNF-R2, and IL-6 are elevated in those with 3 or more failed
treatment trials as compared to those with 1 or 0 failed trials (179), and a variety of
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diverse proinflammatory biomarkers have been shown to be increased in those with TRD
as compared to healthy controls (180,181).
Specific expression combinations of inflammatory biomarkers and genes may be
what contributes to this subtype. This may be why inflammatory biomarkers can have
opposite effects in certain contexts (although this has yet to be elucidated). Interleukin-2
(IL-2) detected before treatment has been associated with treatment resistance in the short
term, but CRP, IL-6, MCP4 elevated post-treatment has been linked with poor long-term
(3-12 months after hospital discharge) response to treatment (174). Furthermore, TRD
patients with high inflammation (as indicated by elevated CRP levels) respond better to
anti-inflammatory agents than those with low to average CRP (182). A follow-up study
found these high inflammation patients displayed a unique lipid and glucose metabolism
gene expression profile which is possibly an indicator of this inflammatory subtype of
depression (183). If this subtype indeed exists, then treatment resistance in depression
may be to a great degree influenced by inflammation or a distinct inflammation-related
profile. Further research is needed to link inflammation and treatment resistance in
depression.
1.5.8 Microglia and Inflammation
As previously mentioned, microglia play an important role in the inflammatory
response as they mediate the cascade by acting as the macrophages of the brain. They
release inflammatory mediators, and are involved in the overexpression of glutamate –
leading to glutamate excitotoxicity – and in the production of quinolinic acid, a potent
neurotoxin, from KYN (184). In chronically stressed mice, there is a decline in the
number of microglia in the hippocampus, as well as decreased activation of said microglia
(185). In individuals with multiple sclerosis, microglial activation is present and is
associated with symptoms of depression (186). In MDD, microglial activity is linked with
increases in levels of IL-6, IL-8, and TNF in the CSF and brain parenchyma, as well as
with a reduction in astrocytes and oligodendrocytes (187,188). This reduction could be
due to monocytes infiltrating the brain parenchyma as a result of increased permeability
of the BBB (188). Suicidal individuals are known to have increased levels of monocytes
in addition to increased activation of microglia and microglial priming in both grey and

22
white matter (189–191). This occurs in these patients regardless of if they fulfill DSM
criteria. The above findings are reflective of cytokine data, wherein individuals with
depressive symptoms as a result of other illnesses or inflammatory challenges experience
microglial activation (133,192–194).
Microglial activation and density can be imaged using positron emission
tomography (PET) tracers, wherein the tracer binds to translocator protein (TSPO) on the
surface of mitochondria of microglia. Setiawan and colleagues reported that, while using
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tracer [ F]N-2-(fluoroethoxyl)benzyl-N-(4phenoxypyridin-3-yl)acetamide ([18F]FEPPA),
TSPO total volume distribution (VT), or TSPO density, was significantly increased by
26% in the prefrontal cortex, 32% in the ACC, and 33% in the insula in patients with a
major depressive episode (195). In particular, the greater TSPO VT in the ACC correlated
with greater depression severity and duration (196). The severity and duration of
unmedicated MDD were strong predictors of TSPO VT, accounting for 50% of variance
in TSPO VT in the prefrontal cortex, anterior cingulate cortex, and insula. Richards et al
repeated the initial results while using [11C]PBR28 in major depressive episode (MDE)
patients, finding that TSPO binding was significantly increased in unmedicated MDE
patients, and could be decreased by psychotherapy (197,198). An additional [18F]FEPPA
study found increased microglial activity in the hippocampus, while a study using
[11C]CK11195 reported higher microglial activity in the ACC, the insula, and the
prefrontal cortex in unmedicated MDD patients as compared to healthy controls
(199,200). In LLD patients, increased uptake was correlated with levels of peripheral
CRP (201). Overall, [18F]- FEPPA studies indicate increased microglial activity in MDD,
and studies using other TSPO-PET tracers reflect these findings.
On the contrary, Hannestad et al (2013) found that TSPO is not elevated in
depression, although they used [11C]PBR28 as their radioligand (202). Another study,
also using [11C]PBR28 as a radioligand, was performed in 10 depressed individuals using
injected LPS, compared to 10 healthy controls. They found that TSPO binding did not
correlate with inflammation or mood even though TSPO levels did increase (203). In
another study, IFNα was administered which led to a decrease in VT in the whole brain,
but with correction this effect was eliminated. Mood changes were apparent in subjects
given IFNα, but no association was found between inflammation and mood (204). This
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could be attributable to differing study methodologies, as well as to differing TSPO tracer
characteristics, or the potential suppression of microglia in specific conditions. Indeed,
some studies have found decreased numbers of glial cells in the subgenual anterior
cingulate cortex in depressed individuals compared to healthy controls (205–207),
suggesting distinct roles for microglia. At this point in time there seems to be no clear
consensus on how microglia should respond and how this may change in response to
depression.
Considering the above, it becomes apparent that the status of microglial activation
in TRD is still unknown. Particularly of note, it is not clear if key frontolimbic regions
such as the insula and ACC exhibit higher microglial activation, and how such activation,
if present, relates to the connectivity between these two regions. In healthy individuals
administered an inflammatory challenge, the resulting depressive symptoms are mediated
by activity of the insula and sgACC (67,194). To further understand neuroinflammation
in the sgACC and the insula, microglial activation in these areas can be measured. In the
subsequent chapter, we examine this issue in human subjects.

1.6 Imaging the Mechanisms of Depression
1.6.1 In Vivo Measures of Inflammation
Inflammation is frequently assessed through measurements of peripheral
inflammatory biomarkers. This method is simple, cost-effective, and easy-to-complete,
and as such has been well-established in literature. Biomarkers will be found at the site of
inflammation, as well as circulating in plasma and serum, and can be measured from
blood samples in addition to urine, saliva, and cerebrospinal fluid. A major drawback of
this technique involves cases when the region of interest is the brain: one is unable to
ascertain neuroinflammation, but rather a whole-body inflammatory state. Post-mortem
brain tissue samples can be acquired to assess biomarker levels directly in the brain with a
high degree of specificity, but these samples come from the endpoint of disease
progression (which is not of interest) and are not generalizable.
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1.6.2 PET Imaging of Inflammation
PET is the most highly sensitive imaging technique and is widely used in the
research of neuropsychiatric disorders, movement disorders, and more. Microglial
activation, and thus inflammation of the brain, can be quantified by detection of
translocator proteins of 18 kDa (TSPO) which are expressed on the surface of
mitochondrial membranes and are upregulated during the immune response. Many studies
over the years have confirmed this upregulation during neuroinflammation (208) as in the
brains of depressed individuals as described above.
The most commonly used TSPO radioligand to study microglia to date has been
[11C]PK11195 which poorly penetrates the blood brain barrier, has poor affinity for
TSPO, high plasma protein binding, and a difficult process for synthesis. Second
generation ligands – ligands developed from lessons learned from [11C]PK11195 – such
as [18F]FEPPA, have a higher brain penetration rate as well as a high affinity for TSPO.
[18F]-labelled radioligands have improved counting statistics and image quality
compared to [11C], in addition to a longer half-life (20.39 minutes vs. 108.9 minutes)
(209,210) which is better suited for clinical imaging. Other [18F]-labelled radioligands
such as [18F]FEDAA1106 and [18F]PBR06 have many favourable properties but have
issues such as being overly lipophilic or can confound quantification through the
production of brain-penetrating metabolites (211,212).
1.6.3 In Vivo Imaging of Brain Network Connections
Magnetic Resonance Imaging (MRI) offers good spatial resolution, is noninvasive, and has good spatial localization for both structural and functional imaging.
Functional MRI (fMRI) applies radiofrequency pulses (RF) on a time-varying basis to
measure variations in neural metabolism. The majority of fMRI imaging uses the bloodoxygen-level-dependent (BOLD) MRI technique to detect changes in levels of
deoxygenated hemoglobin, a measurement which acts as a proxy for neuronal activation.
When an area of the brain is activated, this area will have an increased metabolic rate, and
therefore receive a greater influx of cerebral blood flow to replenish depleted stores of
oxygen and flush out waste products. The oxyhemoglobin will then be converted to
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deoxygenated hemoglobin as oxygen is delivered to the activated area. Initially, there will
be a surge in deoxygenated hemoglobin as the affected area consumes the oxygen, but
within a few seconds the deoxyhemoglobin will be overpowered by oxyhemoglobin as
the body overcompensates for the amount of oxygen that is needed. This event is referred
to as the hemodynamic response. Oxygenated hemoglobin is diamagnetic and
indistinguishable from tissue, but deoxygenated hemoglobin is paramagnetic and creates
gradients in the magnetic field which affect specific MRI signal parameters -- T2 and T2*
relaxation times -- in the blood. The changes can be measured using BOLD fMRI while
the subject is in a “resting state” (in the scanner with no particular thoughts) or in a taskbased situation with a specific set of rules to which the subject must adhere.
Functional connectivity is the statistical probability of two or more regions of the
brain being functionally related in time (213). These distant regions will show correlated
activity in a resting state or in response to a task at the same moment. When regions are
shown to be functionally connected consistently, they are considered to be components of
a network. As a strength, this approach is relatively straightforward and without bias due
to its lack of a priori assumptions. It is important to note that since this method is
correlational, causation cannot be immediately assumed.
1.6.4 In Vivo Imaging of Brain Macrostructure Connections

Along with functional connectivity, depression symptomatology is linked with
alterations in structural connectivity. White matter tracts associated with and connected to
the ACC have been implicated in depression. A prominent white matter tract with
projections from the cingulate gyrus towards the temporal lobe, forming a C shape around
the corpus callosum, is the cingulum bundle. This tract has been linked with emotion,
pain, and executive dysfunction (214,215) and, using diffusion tensor imaging (DTI), its
integrity has been measured in depressed individuals, identifying decreases in fractional
anisotropy and axial diffusivity, and increases in radial diffusivity (216–220). Such
patterns of microstructure alterations have been associated with familial risk for
depression (221), and reductions in fractional anisotropy have been correlated with
depression severity and duration in the cingulum (222). Although the cingulum bundle is
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of great interest for those studying MDD, it is currently unknown how neuroinflammation
is related to its integrity in those with the condition.
DTI is an MRI technique which measures the diffusion of water threedimensionally across the brain using diffusion weighted image (DWI). The diffusion
tensor captured from DWI represents the three eigenvectors (which each correspond to an
eigenvalue, a scaling factor) that characterize water diffusion direction and magnitude,
along the three dimensions, which provides insight into white matter integrity. Diffusion
measured in tissue will be anisotropic (vary depending on direction), and in white matter
anisotropy can be caused by cellular membranes, myelination, and axon density. By
modelling the diffusion tensor, diffusion tensor parameters that describe several aspects
of water diffusion direction and magnitude can be calculated to characterize white matter
macrostructure. The DTI parameters are 1) fractional anisotropy – the relative difference
between the largest eigenvalue and the others, representing microstructural integrity, 2)
mean diffusivity – the average of all three eigenvalues, representing membrane density, 3)
axial diffusivity -- the value of the primary eigenvalue, representing diffusion along the
main white matter tract, and 4) radial diffusivity -- the average of the 2nd and 3rd
eigenvalues, representing demyelination. Statistical analyses of these parameters using
ROIs, voxel-based analyses, or tract-based spatial statistics (TBSS) can be used to
quantify brain macrostructure. ROI analyses can be biased and accurate parcellations of
white matter regions are difficult to achieve. Voxel-based analyses are automated,
spatially-specific, and avoid bias, but registration of individual brain images to a common
space for statistical analysis requires complex algorithms and may not be accurate (223).
TBSS is a recent method which eliminates issues with registration algorithms and the
need to use spatial smoothing to reduce noise, therefore increasing statistical power (223).
Here, TBSS was used to quantify connectivity in the cingulum bundle in relation to levels
of inflammation measured with TSPO PET. However, DTI can be limited by challenges
with tissue type differentiation (partial volume effects) as diffusion is averaged over a
relatively large voxel, and by difficulty resolving crossing fibers – fibers from separate
pathways -- as the tensor can only model a single major fiber direction (224). Thus, DTI
can be difficult to interpret, and depending on the tissue type, brain region, and sample,
the same measure may represent separate outcomes entirely. Overall, DTI is particularly
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useful in the study of neurodegenerative disorders, movement disorders,
neurodevelopment, and aging, but special care must be taken in its interpretation.

Figure 1.3. The cingulum bundle. The cingulum bundle (red) is a prominent white
matter tract which forms a C-shape around the corpus callosum. It has been repeatedly
associated with the pathophysiology of depression. We expect the neuroinflammation to
reduce its white matter axonal integrity.

1.7 Study Outline
Individuals aged 50 years and older with treatment-resistant MDD were compared
to healthy controls. After [18F]FEPPA injection, all individuals were scanned by a hybrid
PET/MR system in order to assess microglial activity and functional/structural
connectivity. PET images were used to obtain mean relative SUV data for the subgenual
ACC and the insula. Functional images were used to assess functional connectivity with
the ACC as a seed. DTI data was used to assess structural connectivity of the cingulum
bundle. The goal was to relate network data to inflammation.
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1.7.1 Study Objectives
1. To assess [18F]FEPPA-traced microglial activation findings in treatment-resistant older
MDD patients as compared to healthy controls.
2. To investigate the relationship between microglial activity and functional connectivity
between the sgACC and the insula.
3. To investigate the relationship between microglial activity and white matter structural
connectivity in the cingulum bundle.
1.7.2 Study Hypotheses
We hypothesized that subjects with MDD would demonstrate increased microglial
activity in the insula and sgACC, and this aberration would be associated with alterations
in functional connectivity between these two regions and with structural connectivity of
the cingulum bundle.
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Chapter 2
2 The Functional and Structural Consequences of
Aberrant Microglial Activity in Major Depressive
Disorder
This chapter has been adapted from the following manuscript submitted to the Journal of
Psychiatry and Neuroscience: The Functional and Structural Consequences of Aberrant
Microglial Activity in Major Depressive Disorder.

2.1 Introduction
Major depressive disorder (MDD), characterised by recurrent cognitive and
emotional dysfunction, is one of the most prevalent psychiatric disorders and a major
contributor toward reduced quality of life (1). While the pathophysiology of MDD is not
fully understood yet, various brain networks that facilitate cognitive and emotional
information processing are thought to be relevant. Two critical brain regions for
predicting therapeutic response and prognosis in MDD are the subgenual anterior
cingulate cortex (sgACC) and the insula. Increased sgACC activity can predict resistance
to treatment -- this hyperactivity normalizes with an improvement in symptoms (2,3) –
and be altered by treatment itself (4–6). Similarly, the metabolic state of the insula,
modifiable through MDD therapies, appears to be a critical determinant of response to
various forms of treatment in MDD (7–9). Insula, through its extensive connectivity with
other brain regions including sgACC, functions to assign salience to emotional and
sensory stimuli and regulates interoception (10,11), the disruption of which has been
associated with the emergence of several cardinal features of MDD (12–14).
Dysfunction of the immune system, and the resulting aberrant load of
neuroinflammation, is increasingly considered to be an important pathway towards
depressive illness, at least in a subgroup of patients with MDD. Aberrant
neuroinflammation has major implications for treatment outcomes; conventional
antidepressants that have little to no anti-inflammatory properties may not be effective,
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thus resulting in a treatment-resistant profile (15,16). Microglia, which have an integral
role in driving the neuroinflammatory response in the brain, have been shown to have
18

increased activity in MDD (16–19), by using PET ligands (e.g. [ F]N-2(fluoroethoxyl)benzyl-N-(4phenoxypyridin-3-yl)acetamide or [18F]FEPPA) that bind to
receptors expressed on the mitochondrial membrane of activated microglia. Microglia
may alter brain network connectivity through means such as synaptic pruning (20); this
likely has downstream consequences on connectivity among brain regions. Prior studies
have linked peripheral and post-mortem markers of inflammation with alterations in
resting-state functional connectivity in MDD (21,22). While excessive microglial activity
has been demonstrated in vivo in MDD, we do not know if this has functional and
structural consequences on brain networks relevant to the pathophysiology of depression.
Subjective depressive consequences resulting from neuroinflammatory triggers in
healthy volunteers are mediated by the neural activity in the insula and sgACC (10,23).
The dysfunction of ACC, in particular its subgenual division, and its altered connectivity
with the insula have been consistently reported in MDD (24–29). The insula, ACC as a
whole, and the sgACC show increased microglial activity and density in MDD
(16,18,19). In the current study, we focus on the microglial activity of insula and sgACC
and the connectivity anchored on these nodes in MDD.
Several white matter (WM) tracts have been implicated in depression. The
cingulum bundle is a WM tract associated with pain, emotion, and executive function
(30,31) that carries a large fraction of projections from the ACC, towards regions that are
critical in the pathophysiology of depression such as the hippocampus (32) and
parahippocampal gyrus (33). In MDD, alterations in integrity of this tract have been
reported and associated with axonal degeneration, familial risk, illness severity and
persistence (34–40). In particular, patients with later-life depression are observed to have
a higher load of WM lesions affecting the cingulum (41); deep-brain stimulation of the
cingulum bundle is a promising treatment option for treatment-resistant MDD (42). We
investigated the potential relationship between microglial activity and cingulum integrity
in MDD.
We hypothesized that in MDD increased [18F]FEPPA -measured microglial
activity in the sgACC and insula would relate to both disrupted connectivity among these
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two nodes, and the severity of MDD. This current study investigated this relationship in
four parts using a hybrid PET/MRI approach: (1) demonstrating aberrant microglial
activity in sgACC and insula in MDD compared to healthy individuals, (2) relating
microglial activity to the observed severity of depression, (3) evaluating the functional
connectivity between the sgACC and the insula in MDD using functional MRI, (4)
establishing the relationship between aberrant microglial activity and the structural and
functional connectivity of the affected regions in MDD in comparison to the healthy
individuals.

2.2 Methods
2.2.1 Participants
Twelve depressed individuals aged 45 years and older referred to the Therapeutic
Brain Stimulation clinic at the Parkwood Institute Mental Health Care Building (London,
Ontario, Canada) were recruited between December 2017 and March 2019 for the study.
PET/MRI data from 23 healthy volunteers recruited for an ongoing dementia imaging
study were included as controls (Table 2.1). Patients were assessed by their treating
psychiatrist per the Diagnosis and Statistical Manual of Mental Disorders, 5th Edition Structured Clinical Interview for DSM-5 to confirm their diagnosis (43).
Symptomatology was reassessed at 6 to 12-month intervals. Up to two weeks before the
scan, patients were administered the Montreal Cognitive Assessment (MoCA), the Beck
Depression Inventory (BDI) test, Clinical Global Impression Severity scale (CGI-S), and
the 17-item Hamilton Depression Rating Scale (HAM-D17) (44–47). The medication
history, level of education, onset of depression, and treatment response were collected at
study enrollment.
All participants were free from confounding neurological or psychiatric disorders,
or other conditions that could confound PET and MR imaging including known history of
infection and autoimmune disorder. Given the known differences in TPSO binding
affinity common to second-generation TSPO PET ligands, participants with low-affinity
binding, which represents < 10% of the population, were excluded to reduce intersubject
variability (48). Genotyping of the TSPO-related polymorphism was performed at The
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London Regional Genomics Centre at Robarts Research Institute and individual TSPO
polymorphism status was included as a covariate in statistical analysis. This study was
approved by the Western University Health Sciences Research Ethics Board and
conducted in accordance with the Declaration of Helsinki ethical standards. All
participants provided written informed consent.
2.2.2 PET/MR Imaging
Individuals were scanned once using a 3T Biograph mMR (Siemens Healthineers,
Erlangen, Germany) utilising a 12-channel PET-compatible head coil in order to obtain
both PET and MRI data in tandem. Each subject was injected with an intravenous bolus
of [18F]FEPPA (185±5 MBq (5±0.1mCi)), synthesized at Lawson Health Research
Institute following a reported method (49). Dynamic PET images were acquired for 90
minutes in list mode, starting immediately following tracer injection. The 60 to 90 minute
post-injection frames were reconstructed to six 5-minute frames using Siemens e7 tools
and an iterative algorithm (ordered subset expectation maximization algorithm; 3
iterations, 21 subsets, 2 mm full-width at half-maximum (FWHM) Gaussian filter, 2.5
zoom factor, 344 × 344 × 127 matrix representing 2 × 2× 2 mm3 voxels), and corrected
for decay, scatter, dead-time, and attenuation using an MR-based approach (50).
A T1-weighted 3D magnetization-prepared rapid gradient echo (MPRAGE)
sequence (slice thickness = 1mm, repetition time = 2000 ms, echo time = 2.98 ms, flip
angle = 9 degrees, acquisition matrix = 256 × 256, and field of view = 256 mm) was used
for generation of 1mm isotropic-voxel-tissue masks for PET attenuation and partial
volume error correction, masking, co-registration of MRI with PET, and spatial
normalization of images into Montreal Neurological Institute (MNI) space. fMRI images
were acquired during rest with eyes opened in a 2 mm isotropic resolution covering the
whole brain with 64 interleaved axial slices (slice thickness = 3 mm, repetition time =
2500 ms, echo time = 30 ms, flip angle = 90 degrees, acquisition matrix = 80 mm × 80
mm, and field of view = 240 mm). A total of 164 volumes were obtained; the first 6 were
discarded to account for magnet stabilization. A 10-min diffusion-weighted imaging
(DWI) scan was acquired using a single-shot EPI sequence with the following
parameters: 64 diffusion-encoding directions; b-values = 0 and 1000 s/mm2; 2x2x2 mm3
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isotropic voxels. Two b0 images were acquired with opposite phase-encoding directions
to correct for susceptibility-induced distortions in DWI.
2.2.3 PET/MR Image Processing
Preprocessing of PET images was done using the SPM12 toolbox
(www.fil.ion.ucl.ac.uk) and in-house MATLAB (2018b; The MathWorks, Natick, MA)
scripts. To compensate for motion, the PET time frames were aligned to the first frame
and averaged to one image volume using the SPM realignment function and converted to
standardized uptake value (SUV) images. T1-weighted images were segmented into grey
matter, WM, and CSF using the segmentation tool in the computational anatomy toolbox
(CAT12) (51). The grey matter segment was then smoothed using an 8 mm kernel to
permit improved alignment of MRI to PET. A whole-brain mask generated from the
cumulative sum of the gray matter, WM, and CSF segments were applied to the PET
SUV images to remove extracerebral voxels. The SUV images were corrected for partial
volume effects (PVE) using the Müller-Gartner method implemented in the PETPVE12
toolbox in SPM (52). To ensure WM and CSF signal contamination were wellcompensated, the WM and CSF segments were eroded in MATLAB with morphological
filtering and connected component analysis using a 2 × 2 voxel size. Point-spread
function (PSF) for PVE correction was set at 5 mm isotropic to model the PSF of the
PET/MRI scanner. The SUV images were spatially normalized to MNI space following
the unified segmentation method (53), smoothed using a Gaussian filter with a FWHM of
10 mm, and count-normalized by the mean SUV in the primary motor cortex to create
relative SUV (rSUV) maps. Masks for the grey regional analyses were generated from the
Automated Anatomical Labeling (AAL3; https://www.gin.cnrs.fr/en/tools/aal/) atlas. The
masks were eroded by 2 voxels as described above to restrict inclusion of voxels outside
of the ROI and minimize misalignment of ROI to individual PET images. Mean rSUV
values were extracted from left and right sgACC and insula for statistical analysis. The
sgACC has been distinctly reported to have higher microglial activity in voxelwise
studies of MDD, while the insula has been reported to have higher microglial activity in
ROI studies (16,18,19). In addition, we also explored other subregions of ACC (pregenual
and supracallosal ACC) in an exploratory manner, and report uncorrected results.
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fMRI images were pre-processed using the default direct processing pipeline in
CONN toolbox (Matlab2018b; www.nitrc.org/projects/conn, RRID:SCR_009550) and
motion parameters were included as regressors. A seed-based analysis with the sgACC as
a seed region was performed between patients and controls (excluding four control
individuals due to frontal artifacts) including covariates (age and sex). Pearson’s r-to-zscores representing functional connectivity between the sgACC and the insula were
extracted for statistical analysis. DWI data were preprocessed using an in-house pipeline
to generate diffusion tensor imaging (DTI) scalar maps; fractional anisotropy (FA), mean
diffusivity (MD), axial diffusivity (AD), and radial diffusivity (RD) maps (54). The DTI
scalar maps were spatially normalized to MNI space using a three-step registration
algorithm (consisting of rigid, affine, and deformable transformations to a standard MNI
T1 1-mm template) in ANTs (55). Region-based analyses of DTI scalars were performed
by calculating mean FA, MD, AD, and RD values in the cingulum bundle WM pathway
using regional masks from the John Hopkins White Matter Atlas (56). While there are
multiple metrics available from DTI, increased AD has been associated with axonal
integrity (57,58) and increased extracellular water content; increased extracellular water
content is a biomarker of neuroinflammation (59). Although metrics such as FA, MD, and
RD may likewise be sensitive to water content changes, the specific activity of microglia
may be more closely related to AD as they aid in engulfing axonal debris (60,61). We
chose AD as the primary DTI index of interest for this analysis.
2.2.4 Statistical Analysis
Covariates of no interest included age, sex, and TSPO status. Multiple linear
regressions including covariates of no interest were performed to assess differences in
regional microglial activity (rSUV) and in functional connectivity (z-scores) to determine
the effect of diagnostic status. Given the 4 ROIs chosen a priori, a Bonferroni-corrected
statistical threshold of 0.0125 was used as the threshold for significance. A multiple
linear regression per ROI was performed with non-linear locally estimated scatterplot
smoothing (LOESS) to assess the relationship between [18F]FEPPA uptake and HAM-D
scores, and between [18F]FEPPA uptake and DTI measures of the cingulum bundle,
adjusting for covariates as above (threshold p=0.05).
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To test the effects of functional connectivity on microglial activity, first a single factor
representing all functional connectivity variables (left sgACC to left insula; left sgACC to
right insula; right sgACC to left insula; right sgACC to right insula; left sgACC to right
sgACC; left insula to right insula) was derived using principal components analysis
(PCA). Next, a non-linear regression predicting left sgACC microglial activity with the
PCA-derived connectivity variable and covariates of no interest was run across the whole
sample. The connectivity variable and age were included as non-linear (LOESS)
predictors while the categorical variables of diagnostic status, sex, and TSPO status were
linear. The same models (excluding diagnostic status as a predictor) were run on patients
and controls separately. Non-linear regressions were used to relate functional connectivity
with [18F]FEPPA uptake, as both increased (62) and decreased (63,64) connectivity has
been reported in preclinical and clinical studies of inflammatory markers, indicating the
likelihood of a U-shaped relationship between microglial activity and functional
connectivity. Including age and the PCA-derived factor as non-linear in the model
reduced the model error significantly compared to the linear model. The number of knots
included in the non-linear model was selected based on the generalized cross-validation
(GCV) method, which uses leave-one-out cross-validation to minimize the model’s
prediction error, thus minimizing overfitting. All statistical tests were run using SAS
9.4M7 (Raleigh, North Carolina) with a statistical threshold of p=0.05.
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2.3 Results
We found a significant increase in [18F]FEPPA uptake in patients when compared
to controls in the left sgACC (t=2.684; p=0.012) while all other regions except the right
pregenual ACC showed higher [18F]FEPPA uptake than controls but did not survive
correction (Figure 2.1). [18F]FEPPA uptake from the left and right insula were significant
predictors of HAM-D scores in a linear model including non-linear age (left p=0.039;
right p=0.037) (Figure 2.2). Z-scores representing functional connectivity between the
sgACC and the insula revealed no significant reduction in pairwise connectivity (Figure
2.3; right sgACC-right insula p=0.053; left sgACC-left insula p=0.474; left sgACC-right
insula p=0.059; right sgACC-left insula p=0.209).

Table 2.1. Participant Demographics.

a

Variablea

Depressed (n=12)

Healthy (n=23)

Sex

8 F, 4 M

11 F, 12 M

Age (yr.)

54.9 ± 4.5

60.3 ± 8.5

TSPO Statusb

8 HAB, 4 MAB

12 HAB, 11 MAB

MoCAc

26.5 ± 2.1

N/A

HAMD-17

18.9 ± 7.1

N/A

Age of Onsetd (yr.)

30.4 ± 13.8

N/A

All means include ± SD.
HAB=high affinity binder, MAB=mixed affinity binder.
c
Missing data from 1 subject.
d
Missing data from 2 subjects.
b
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Figure 2.1. Differences in mean relative standard uptake values (rSUV) per region of
interest (ROI). ROIs included left and right sides of (A) the whole anterior cingulate
cortex (ACC; in violet), (B) its pregenual (green), subgenual (red), and supracallosal
(blue) subregions, as well as (C) the insula. (D). ROIs chosen a priori for hypothesis
testing are highlighted in the red box. Linear regressions were run for each ROI
(including covariates), finding significant differences between patients (N=12) and
controls (N=23) in the left subgenual ACC (p=0.012) when partial volume correction is
used.
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Figure 2.2. The relationship between mean relative standard uptake values (rSUV)
from the insula and HAM-D scores. A linear regression including age as a non-linear
factor (LOESS) and sex as covariates found that both (A) left insula [18F]FEPPA activity
(represented by rSUV; p=0.039) and (B) right insula [18F]FEPPA activity (p=0.037)
significantly predicted HAM-D scores in major depressive disorder patients (N=12).

54
Figure 2.3. Differences in subgenual anterior cingulate cortex-insula functional
connectivity. A linear regression including age and sex as covariates found that
functional connectivity (represented by Pearson’s r-to-z scores) did not significantly
differ between patients (N=12) and controls (N=19) but was borderline significant in the
connection between the right subgenual anterior cingulate cortex (sgACC) and the right
insula (p=0.053) and between the left sgACC and the right insula (p=0.059). sgACCL is
left subgenual anterior cingulate cortex; ICL is insular cortex left; sgACCR is right
subgenual anterior cingulate cortex; ICR is insular cortex right.

Figure 2.4. The relationship between mean relative standard uptake values (rSUV)
and functional connectivity. Non-linear regressions including a PCA-derived functional
connectivity factor and age as non-linear factors (LOESS), and linear covariates of no
interest were run in order to assess the impact of functional connectivity (represented by
Pearson’s r-to-z scores) between the subgenual anterior cingulate cortex (sgACC) and
insula on [18F]FEPPA activity (represented by rSUV). (A) All six pairwise connectivity
variables between bilateral sgACC (red) and insula (yellow) were used to create a single
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principal factor. (B) When using the whole sample (N=31), increasing functional
connectivity was associated with a sinusoidal-like change in [18F]FEPPA activity
(p=0.044). (C) In patients (N=12), increasing functional connectivity was associated with
first a decrease, then an increase in [18F]FEPPA activity (p=0.015) while (D) in controls
(N=19) there was again a sinusoidal relationship between connectivity and activity
(p=0.035).

Figure 2.5. The relationship between microglial activity and structural connectivity.
Linear regressions including age as a non-linear covariate, and sex, TSPO status, and
diffusion tensor imaging metrics of white matter integrity as linear predictors were run in
order to assess the impact of white matter integrity of the cingulum bundle on microglial
activity in MDD patients (N=12). (A) Increasing axial diffusivity was associated with an
increase in microglial activity (p=0.023) (B) Increasing fractional anisotropy was not
significantly associated with microglial activity (p=0.843). (C) Increasing mean
diffusivity was not significantly associated with microglial activity (p=0.072). (D)
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Increasing radial diffusivity was not significantly associated with microglial activity
(p=0.173).
We then tested if functional connectivity between the sgACC and the insula
(derived from a single principal factor explaining most of the variance of six pairwise
connectivity variables between bilateral sgACC and insula = !!"" = 6) is a significant
factor explaining [18F]FEPPA uptake in the left sgACC, the region with higher uptake in
MDD. This was first done across the whole sample, finding that functional connectivity
was a significant non-linear predictor of microglial activity (p=0.044; Figure 2.4B). When
investigating patients and controls separately, functional connectivity was a significant
non-linear factor for both groups in explaining left sgACC [18F]FEPPA uptake (patients
p=0.015; controls p=0.035). Interestingly, higher [18F]FEPPA uptake related to optimal
(near-average) connectivity in the healthy subjects, while in MDD, both reduced and
increased connectivity occurred with higher [18F]FEPPA uptake (Figure 2.4B & 2.4D).
Finally, we assessed the relationship between microglial activity of the left sgACC
and WM integrity of the cingulum bundle. We found that AD, a measure of unidirectional
diffusion, from the left cingulum bundle significantly predicted microglial activity of the
left sgACC in a linear model (p=0.023) (Figure 2.5A) but FA, MD, and RD did not
significantly predict microglial activity (FA p=0.843; MD p=0.072; RD p=0.173) (Figure
2.5B,C,D).

2.4 Discussion
In the current study, we demonstrated 3 key findings relevant to the
neuroinflammation hypothesis of MDD: (1) a significantly increased microglial activity
in the left sgACC occurs in patients being treated for MDD; (2) the higher the microglial
activity in the insula, the less severe the HAMD scores; (3) left sgACC microglial activity
influenced the functional connectivity between the sgACC and the insula and the axonal
integrity of the cingulum bundle in MDD.
Setiawan and colleagues (2015) previously found increases in microglial density
in the prefrontal cortex, the insula, and the ACC using [18F]FEPPA in MDD, and other
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groups have replicated these results using analogous [11C]-PBR28 (16,18). Here, we
localized these previous findings to the sgACC as a specific site of increased [18F]FEPPA
uptake. The findings of Su and colleagues (2016) using a voxel-wise search in LLD (19)
corroborate our localisation to sgACC.
We found that microglial activity from the left and right insula predict HAM-D
scores, but this relationship is negative. Prior studies have reported an increase in severity
of depression with increasing microglial activity (16), but individuals with increased
neuroinflammation showed better treatment outcomes as well (65). Our sample consisted
of patients receiving long-term treatment, wherein depression severity was low among
those with higher microglial activity. It is possible that the inverse relationship we report
is more reflective of the post-treatment improvement in outcome in a subset of patients
inclined to have higher neuroinflammation, as reported by (65), or of neuroprotective
microglial activity (66). The relationship between symptom severity and microglial
activity may differ according to stage of treatment, phase of illness, or treatment-resistant
profile. It is also possible that different measures of microglia (rSUV vs. VT) between
studies may have affected results, although the extent of this effect is unclear.
Levels of sgACC-insula functional connectivity were likewise dependent on
diagnostic status, which has previously been elucidated (67). As hypothesized, we then
found that functional connectivity between the sgACC and the insula is significantly
associated with microglial activity from the left sgACC in both patients and controls. To
our best knowledge this is the first study to use PET/MR to investigate the functional
consequences on [18F]FEPPA uptake in MDD. A study investigating the network
pathophysiology as it relates to neuroinflammation (also using PET/MR) in Alzheimer’s
dementia found that those with increased radioligand binding have abnormal functional
connectivity (68). Although this study was done in Alzheimer’s patients, later-life MDD
and cognitive impairment are highly correlated (with depression being an early risk factor
of dementia), and the current results highlight a possible neuroinflammatory basis for
both conditions.
We note that patients with MDD have a V-shaped relationship between microglial
activity and functional connectivity that is distinct from healthy controls. The healthy
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individuals showed an initial increase in microglial activity with increasing functional
connectivity, reaching a peak, with a subsequent decrease. In patients, both an increase
and decrease in functional connectivity was seen in conjunction with higher levels of
microglial activity. On a speculative note, these observations may reflect 2 different states
of the microglia – neurotoxic state, seen in patients, where higher levels relate to extremes
of functional connectivity, and a neuroprotective or surveillance state, seen in healthy
controls, where optimal functional connectivity requires sufficiently high microglial
activity, maintaining neuronal communication (69). A dynamic pattern of microglial
activation, particularly the early increase and later switch to decreased activity, have been
identified in a previous study chronicling the transition from cognitively normal to mild
cognitive impairment to Alzheimer’s disease (69). The speculation presented here needs
further confirmation in a longitudinal hybrid PET/MR study using a larger cohort of
MDD with age-matched and medication-naïve healthy adults.
When relating WM macrostructural connectivity to microglial activity, we found
that AD (diffusion in a direction parallel to the WM tract) of the cingulum bundle was
significantly associated with microglial activity in the sgACC. Currently, there is no
consensus on the findings of specific DTI metrics in MDD, and meta-analyses have
posited that characteristic patterns may be restricted to subsets of the disease (30,36). An
increase in AD with increasing microglial activity may denote alterations in WM
microstructure (i.e., axonal integrity), and since AD is associated with neuroinflammation
(59) and microglia in particular (60,61), it is then, perhaps, that neuroinflammation may
negatively impact WM integrity of the cingulum bundle. This relationship may signal
increased axonal injury, prompting microglia to clear up axonal debris, or chronic
activation of microglia which may facilitate axonal degeneration. Furthermore, although
FA, MD, and RD were not significantly associated with microglial activity, their general
trends are reflective of age-related patterns of axonal degeneration (70,71). This may then
indicate that microglia have a similar effect as age which lends added support to a shared
mechanism between Alzheimer’s disease and depression.
While the specifics of how microglia are able to influence brain connectivity are
ambiguous at best, it is possible that microglia may alter connectivity through synapse
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pruning. Remodeling of neuronal circuits is an important function of microglia along with
their role in the immune response. Abnormalities in this remodeling function can have
negative impacts upon synaptic plasticity as well as behaviour (20). The remodeling
function is mediated by microglia-neuron crosstalk, a reciprocal communication which
when dysregulated may be involved in depression (20). Manipulation of the C-X3-C
Motif Chemokine Receptor 1 (CX3CR1) pathway, wherein microglia-neuron
communication is prominent, can affect and induce depressive-like behaviour in mice
(72–74). Reduced CX3CR1 signaling, and therefore reduced transmission between the
two cell types, can affect the efficiency of synapses to transmit signals and may result in
modified connectivity, although there are many microglia-neuron signalling pathways
through which this can occur; this includes microglial decline and senescence (75,76).
While microglia have numerous states of activation, activation specific to inflammation
has been linked with altered synaptic current in hippocampal neurons, meaning there is
some precedent to these findings (77,78).
Our study has a number of strengths including the use of hybrid PET/MR that
mitigates the interval-related confounds that can affect multimodal acquisitions
(improved spatial and temporal co-registration), correcting for genetic variations in TSPO
status, as well as the use of a second-generation TSPO ligand. But we were limited by the
sample size (increasing risk for type II error for exploratory analyses), a lack of taskencoded fMRI data to further validate the relevance of the observed functional
dysconnectivity, and use of a MDD cohort which was not medication-naïve. Medications
could have anti-inflammatory properties which could alter intrinsic brain activity and
influence functional states. Nevertheless, we were sufficiently powered to detect the
group differences as reported. Using previously reported effect sizes for the association
between microglial activity and depression severity ( r=+0.63) (16) and assuming a power
of 80%, with a type I error rate of 5% and a type II error rate of 20%, we estimated that a
minimum of 12 patients would be sufficient to detect regional-level differences.
Secondly, the use of SUV and reference regions as compared to other methods such as
kinetic modelling and supervised cluster analysis further limits the strength of our
findings and employing these methods in the future will be necessary for confirmation of
our results (79).
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TSPO imaging is a promising non-invasive tool for research of in vivo responses
to inflammation; nevertheless, there are inherent limitations to its use. Microglial
activation is described as pro-inflammatory or anti-inflammatory, but this idea is shifting
due to emerging research on the ever-changing inflammatory state/morphology of glial
cells in response to the environment. An increase in TSPO expression has been associated
with both pro-inflammatory and anti-inflammatory states, and TSPO-specific
radioligands are unable to distinguish the different states (80,81). This could be due to the
states existing in a continuum rather than a binary. It may also be that these TSPOradioligands measure microglial density rather than microglial activation, and that they
represent a combination of microglial as well as astrocytic signalling (82,83). This lack of
specificity in inflammatory states may also be a challenge for other radioligands designed
to image neuroinflammation by targeting other inflammatory processes besides TSPO,
including emerging radioligands that specifically bind to microglia and not astrocytes
(84). In addition, TSPO imaging is constrained by a rs6971 gene polymorphism, which
we have adjusted statistically in the current work.

2.5 Conclusions
In general, our study first highlights the central role that activated microglia may
play in key brain circuits to influence the mechanistic processes (axonal integrity,
functional connectivity) and behavioural phenotypes (symptom severity) relevant to
depression. Secondly, our work reinforces the need for hybrid PET/MR as a translational
neuroimaging tool. Linking mechanistic hypothesis at a receptor/cellular level observed
using PET, to network-level dysfunctions observed using DTI/fMRI is a crucial step to
generate a more systemic understanding of the pathophysiology of psychiatric disorders.
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Chapter 3
3 Conclusions
3.1 Summary
Throughout the current thesis we have aimed to understand the relationship
between FEPPA-measured microglial activity and both functional and white matter
connectivity in MDD as this has not been previously elucidated. We have concluded that
(1) microglial activity from the left sgACC is significantly increased in MDD, (2) insular
microglial activity is negatively associated with depression severity, (3) functional
connectivity between the sgACC and insula is decreased in MDD, (4) microglial activity
from the left sgACC is non-linearly related to functional connectivity and (5) white
matter connectivity is linearly associated with microglial activity.
The diagnostic status-dependent differences in microglial activity and functional
connectivity have been well-established in previous literature. The disparity in microglial
activity between patients and controls reflects our current understanding of microglia as
having an important role in depression symptomatology. The negative association
between microglial activity and depression severity may be a post-treatment improvement
in outcomes in those with higher neuroinflammation as our sample consisted of
individuals receiving long-term treatment (1).
The double peaks in microglial activity in relation to functional connectivity may
be the result of two microglial phenotypes of activation (2): a neurotoxic state which
occurs in patients at the lowest extreme of functional connectivity, and a neuroprotective
state in healthy controls which requires high microglial activity at optimal functional
connectivity to maintain microglia-to-neuron crosstalk.
Increased AD of the cingulum bundle is associated with decreased microglial
activity. When considering all DTI metrics (decreased FA and increased MD, AD, and
RD with increasing microglial activity) together, it becomes apparent that the effect of
microglial activity on white matter (or vice versa) is similar to age-related effects,
possibly signalling white matter axonal degeneration (3,4).
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3.2 Significance
MDD is a heterogeneous condition which cannot be fully explained at the time of
this thesis. This makes finding the most effective treatment difficult, especially in those
with TRD; in some cases, the most effective treatment has yet to be recognized as a
viable option. MDD diagnosis is further complicated by age, through which we see
distinct differences in those with MDD and those with LLD. These distinct differences
have not been widely studied to date, contributing toward a large gap in knowledge. It
becomes imperative that a better-cultivated understanding of MDD is acquired for
development of novel treatments which are suited for specific subsets of depression.
Considering this, the results of the current study are significant. We have further studied
the specifics of microglial activity in depression and related this with functional and
structural connectivity. This is completely novel as no other groups, to the best of our
knowledge, have related microglial activity with both functional and structural outcomes
in MDD. What is especially important about this development is that we are able to better
understand the interplay between different brain systems, something which has not been
done extensively in depression. These separate systems function in tandem to produce
what we know as clinical depression, and while we know a great deal about each one,
with limitations in current research methods, the ways in which they work together are
relatively unknown.
Building on this further, current research has singled in on the ability of antiinflammatory agents to reduce severity of depression symptomatology. While at this
moment anti-inflammatory agents and the phenomenon of neuroinflammation itself are
nowhere near assiduously studied, their recent rise in research fascination has made our
study apt for filling this gap in knowledge. It therefore becomes possible that antiinflammatory agents can be recognized as viable MDD adjuvant treatment options in the
future. Understanding this relationship may lead to a breakthrough in the future of
depression treatment – something which is sorely needed considering the current lack of
novel options.
Our results are reflective of previous studies of Alzheimer’s disease, further
establishing a link between the two conditions. It has been previously found that those
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with late-life depression are at risk for dementia; since the microglial activity in our
population reflects that of the decline into Alzheimer’s, it may be that microglia play a
pivotal role in disease progression, and likewise in the concurrent development of
Alzheimer’s. At this point this is speculation, but it illuminates a potential avenue for
research into dementia prevention and treatment.
MDD is the leading cause of disability today. It affects one’s productivity, one’s
mood, and can lead one to taking their own life. It is not limited in who it affects, being
the second leading cause of death among young Canadians (5). Such an illness cannot be
taken lightly and any advancements in our understanding of it can aid in improving and
saving lives. The importance of this cannot be understated; depression is isolating and
deadly and with additional research we get closer to exceeding the current limitations of
treatment.

3.3 Limitations
While the results shown are promising, as is the case with most studies they do not
come without certain considerations. First and most glaringly, the sample size used in the
current study is low. While our calculations of power do suggest that this sample size is
enough to see significant differences, this is the absolute minimum. The choice
in individuals within our sample is flawed as well. Those in the depressed cohort were not
restricted based on their medications, and we cannot be sure what anti- or proinflammatory effects they may have. While the controls were age-matched (+/- 5
years), in later life such an age disparity can have a significant impact. As previously
mentioned in Chapter 1, there are physical and symptomological differences
between MDD and LLD. This can completely change how the illness presents itself and
how it arises.
Secondly, the detection of microglial activity from TSPO in itself is
challenging. TSPO expression is not limited to microglia, as it can be overexpressed
in reactive astrocytes (6), withal in peripheral macrophages which may be able to cross
the BBB to reach the brain (Dupont A.C. et al., 2017). It should be noted that levels of
TSPO in astrocytes can become overexpressed during glutamate excitotoxicity, which
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may pose problems as glutamate excitotoxicity is posited to be a significant factor
in depression outcome (7). But this worry seems to not be of great consequence, as
the contribution of TSPO from microglia may be about 7x greater than that of astrocytes,
and the contribution of TSPO from these astrocytes has not yet been found to make a
significant contribution toward the PET image (8). Nonetheless, the specificity of TSPO
PET tracers in microglial binding should be considered in the future.
Specificity of TSPO tracers to the type of microglial activation is another
confounding factor. Microglia, previous to activation, are highly susceptible
to environmental signals. Depending on the environment, when activated they can
be described as either pro-inflammatory (M1) or anti-inflammatory (M2); the M2 state is
thought to be less prevalent and can be activated by anti-inflammatory cytokines in
addition to apoptotic cells and myelin debris, leading to tissue repair. The fact that it is
possible for both of these responses to be active and that TSPO tracers seemingly do not
distinguish between the two confounds interpretations of microglial activation. Moreover,
the idea of concrete categories of microglial activity is shifting as it is theorized that the
states exist in a continuum rather than a binary. It may also be that these TSPOradioligands measure microglial density rather than microglial activation (9).
Thirdly, the choice in radiotracers and study design seems especially important,
as there is no single convincing answer to the direction of microglial activity in MDD.
Each study uses a different TSPO tracer, and studies are able to both replicate and
completely deny previous findings depending on the tracer used. Considering that FEPPA
has a greater specificity to TSPO than many other radioligands, it can be assumed that
studies using FEPPA are more reliable and accurate. The effectiveness of TSPO tracers is
further questioned when considering which ones may
be impeded by MDD pathophysiology. A recent study by Turkheimer et al. found that in
states of low-grade inflammation (in MDD and during inflammatory inducer injection in
healthy individuals) uptake of TSPO tracers into CSF and brain parenchyma is decreased
as compared to healthy controls due to a reduction in BBB permeability (10). It should be
noted that the tracers used in this study were [11C]PK11195 and [11C]PRB28, not
FEPPA. [11C]PK11195, while the first and most widely used TSPO radiotracer, has
a short half-life and low signal to noise ratio due to high nonspecific binding and
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lipophilicity, and may not reflect FEPPA activity. [11C]PRB28 presents much of the same
issues as [11C]PK11195 despite being an analogue to FEPPA.
In conjunction with the issues related to choice of TSPO tracer, another
consideration in interpretation of these results is that TSPO tracer uptake increases with
age. A study done by Kumar and colleagues in healthy children and adults (age range of
adults 20-49) found that adults overall have increased uptake of [11C]PK11195 while the
distribution of TSPO tracer is not altered between groups (11). Given the difference in
age between our control group and our patient group (with controls being about 5 years
older and more definitively in a LLD categorization), it may be that the difference we see
in microglial activity between patients and controls is diminished by the disparity in age.
It is known that increased inflammation is associated with older age, but the exact origin
of such inflammation is not fully understood.
Finally, the choice of the reference region method of data normalization for the
PET data is controversial. Reference regions must be picked carefully; they must have no
significant differences in tracer uptake between patients and controls, and they must have
relatively little TSPO tracer uptake. There exists no area of the brain with no tracer
uptake, and as such there is no perfect reference region. A few reference regions have
been validated in depression: the cerebellum is a common choice due to its large size,
lending itself to greater stability. Reference regions are typically used as a simple
alternative in the absence of arterial blood data. In the current study this data was not
available, and we were unable to accurately model the tracer kinetics. Supervised cluster
analysis methods are available to create supervised reference regions, but their
development is time consuming.

3.4 Future Directions
While we have found a connection between functional connectivity and
neuroinflammation-related molecular activity in depression, this is only the beginning of
fully understanding this relationship. Due to the limitations above, the results must be
supported by future work and replicated by other groups in order to confirm their
authenticity.
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In the future, it would be prudent to explore methods for absolute quantification of
microglia that do not rely on reference region normalization. Absolute quantification of
PET requires measurement of the input function – the time-dependent concentration of
the PET tracer in blood plasma – to quantify the PET tracer concentration in tissue using
tracer kinetic models. Although PET tracer kinetic modelling would allow for increased
accuracy of PET measurements with fewer confounders, the need for serial arterial blood
sampling makes this approach relatively invasive. Less invasive absolute quantification
alternatives such as supervised cluster analysis would eliminate some of the issues
associated with reference region-based normalization, as it uses a data-driven approach to
identify the most suitable reference region.
As well, it would enrich the current findings if serum inflammatory biomarkers
were measured as to indicate levels of whole-body inflammation. Peripheral
inflammatory biomarkers have been linked with dysfunction in connectivity in MDD
(12), so bringing all of these factors together would solidify our conclusions.
An interesting finding was the relationship between microglial activity and functional
connectivity and how this reflected previous results found in Alzheimer’s disease.
Although our subjects were older, they were not fully at risk for Alzheimer’s or
other forms of dementia/cognitive impairment. This means it is possible that we are
seeing a trend in microglial activity associated with age which may predict Alzheimer’s
prognosis. In the future it would be intriguing to explore whether there are subtypes of
microglial activation in the years leading up to being at risk for dementia, and if this is
related to factors such as stress exposure. In order to do so, a larger sample size would be
needed, as well as longitudinal data.
Finally, we would be interested in relating the current findings to alternative
imaging parameters, such as glutamate and glutathione, and in other brain regions, such
as the striatum, in order to build a more cohesive story about depression as a whole.

3.5 Concluding Remarks
The results of this thesis suggest that inflammation is critical in depression and its
manifestation. It moderates the severity of depressed mood and can affect both functional

74
and structural connectivity; thus, evanescent inflammation may have a longstanding
impact of mood changes, as seen in post-viral depressive episodes. These findings are
reminiscent of previous dementia and aging studies, giving insight into the interplay
between separate systems and how their interactions contribute to clinical diagnostic
status at large. Our work opens the possibility of using less expensive, more accessible,
and less invasive DTI/fMRI metrics as a measure of the effect of reducing inflammation
to treat depression.
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